IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Clinical trial NCT03564821 · COMPLETED

Trial details

NCT number: NCT03564821
Sponsor: Massachusetts General Hospital
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

IDH1 Mutation Myeloid Neoplasms

Start date: 2019-01-16
Primary completion: 2022-05-22
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.